ANKMY2

Across TCGA pan-cancer cohorts, ANKMY2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ANKMY2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ANKMY2 RNA is repressed in tumor relative to normal tissue. In most cancer types ANKMY2 is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, LIHC, and COAD are the cancer types where ANKMY2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKMY2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.818	<.001	10	view →
LIHC	Male	All	+0.828	<.001	8	view →
COAD	All	All	−0.357	.003	7	view →
UCEC	All	II,III,IV	−1.208	<.001	6	view →
BRCA	All	All	−0.573	<.001	6	view →
CHOL	All	All	+1.587	<.001	5	view →
BLCA	Male	All	−0.785	.001	3	view →
PRAD	All	All	−0.625	<.001	2	view →
KIRP	All	IV	+0.535	.029	2	view →
READ	All	II,III,IV	−0.552	.033	1	view →
STAD	Male	All	+0.457	.034	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ANKMY2–THCA

Open the THCA breakdown →